Integrative Molecular Characterization of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with and mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. SIGNIFICANCE: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with and mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene in epithelioid MPM...

Citing Articles

FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma.

Vecchio E, Gallo R, Mimmi S, Gentile D, Giordano C, Straface E Commun Biol. 2025; 8(1):324.

PMID: 40016284 PMC: 11868402. DOI: 10.1038/s42003-025-07754-0.

The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.

Torricelli F, Spada F, Bishop C, Todd K, Nonaka D, Petrov N J Transl Med. 2025; 23(1):208.

PMID: 39980060 PMC: 11844119. DOI: 10.1186/s12967-025-06193-z.

Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network.

Poma A, Bruno R, Petrini I, Di Stefano I, Celi A, Sbrana A Cancers (Basel). 2025; 17(3).

PMID: 39941836 PMC: 11815884. DOI: 10.3390/cancers17030469.

Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice.

Shindyapin V, Gubernatorova E, Gorshkova E, Chicherina N, Sysonov F, Yakovleva A Cells. 2025; 13(24.

PMID: 39768223 PMC: 11675005. DOI: 10.3390/cells13242135.

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F Nat Commun. 2025; 16(1):423.

PMID: 39762248 PMC: 11704051. DOI: 10.1038/s41467-024-55316-5.

References

Chee J, Robinson B, Holt R, Creaney J . Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies. Chest. 2016; 151(4):891-897. DOI: 10.1016/j.chest.2016.10.007. View

Kang H, Kim H, Lee S, Mendez P, Kim J, Woodard G . Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016; 7(7):8321-31. PMC: 4884995. DOI: 10.18632/oncotarget.7032. View

Vaske C, Benz S, Sanborn J, Earl D, Szeto C, Zhu J . Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010; 26(12):i237-45. PMC: 2881367. DOI: 10.1093/bioinformatics/btq182. View

Illei P, Rusch V, Zakowski M, Ladanyi M . Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003; 9(6):2108-13. View

Williams M, Kirschner M, Cheng Y, Hanh J, Weiss J, Mugridge N . miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015; 6(27):23480-95. PMC: 4695131. DOI: 10.18632/oncotarget.4346. View

Shaw T, Zhang X, Huo Z, Robertson D, Lovell P, Dalgleish A . Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity. Int J Gynecol Cancer. 2016; 26(5):833-8. DOI: 10.1097/IGC.0000000000000697. View

Nik-Zainal S, Van Loo P, Wedge D, Alexandrov L, Greenman C, Lau K . The life history of 21 breast cancers. Cell. 2012; 149(5):994-1007. PMC: 3428864. DOI: 10.1016/j.cell.2012.04.023. View

Nowak E, Lines J, Varn F, Deng J, Sarde A, Mabaera R . Immunoregulatory functions of VISTA. Immunol Rev. 2017; 276(1):66-79. PMC: 5702497. DOI: 10.1111/imr.12525. View

Liu J, Yuan Y, Chen W, Putra J, Suriawinata A, Schenk A . Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015; 112(21):6682-7. PMC: 4450438. DOI: 10.1073/pnas.1420370112. View

10.

LaFave L, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A . Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015; 21(11):1344-9. PMC: 4636469. DOI: 10.1038/nm.3947. View

11.

Lines J, Sempere L, Broughton T, Wang L, Noelle R . VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014; 2(6):510-7. PMC: 4085258. DOI: 10.1158/2326-6066.CIR-14-0072. View

12.

Zheng S, Cherniack A, Dewal N, Moffitt R, Danilova L, Murray B . Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016; 29(5):723-736. PMC: 4864952. DOI: 10.1016/j.ccell.2016.04.002. View

13.

Carbone M, Ferris L, Baumann F, Napolitano A, Lum C, Flores E . BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10:179. PMC: 3493315. DOI: 10.1186/1479-5876-10-179. View

14.

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

15.

Crispi S, Fagliarone C, Biroccio A, DAngelo C, Galati R, Sacchi A . Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010; 70(3):271-9. DOI: 10.1016/j.lungcan.2010.03.005. View

16.

Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K . Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006; 66(6):2970-9. DOI: 10.1158/0008-5472.CAN-05-3907. View

17.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

18.

Yap T, Aerts J, Popat S, Fennell D . Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17(8):475-488. DOI: 10.1038/nrc.2017.42. View

19.

Luchini C, Veronese N, Yachida S, Cheng L, Nottegar A, Stubbs B . Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis. Genes Chromosomes Cancer. 2016; 55(10):741-9. DOI: 10.1002/gcc.22381. View

20.

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H . High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015; 10(4):565-76. PMC: 4408084. DOI: 10.1097/JTO.0000000000000471. View